Abstract
Several malignant solid tumors are characterized by high fibroblast activation protein alpha (FAPα) expression. FAPI-46 is a theranostic ligand for FAPα-directed PET imaging and subsequent radioligand therapy (RLT). We report efficacy and safety of 90Y-FAPI-46 RLT in patients with advanced sarcoma, pancreatic cancer (PDAC) and other cancer entities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
